stockrow
Friday 6 November 2026
Export CDNA’s income statement to Excel — free account
CareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
76.96
8.90
−10.37%
Follow CDNA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
26.10 | 13.26 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.81 | 3.20 | 2.15 | 2.64 | |
P/FCF ratio |
58.22 | 17.64 | 14.03 | 29.06 | |
P/Operating CF |
266.36 | 47.93 | 204.94 | 46.99 | |
P/B ratio |
7.25 | 3.45 | 2.83 | 3.31 | |
Price to Tangible BV |
16.45 | 3.95 | 3.68 | 4.35 | |
EV/Sales |
6.31 | 2.39 | 1.70 | 2.18 | |
EV/EBITDA |
22.21 | 8.43 | 118.53 | 0.00 | |
EV/Operating CF |
45.49 | 11.70 | 9.64 | 19.73 | |
EV/FCF |
53.96 | 13.18 | 11.11 | 24.00 | |
Quick Ratio |
2.15 | 4.35 | 2.93 | 2.45 | |
Current Ratio |
2.31 | 4.58 | 3.40 | 2.86 | |
Net Debt/EBITDA |
(14.58) | (3.17) | (25.20) | 177.21 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.93 | 0.94 | 0.92 | 0.84 | |
Operating CF/Net income |
0.66 | 0.28 | 1.54 | (5.20) | |
Capex/Depreciation |
(0.18) | (0.41) | (0.61) | (0.39) | |
Research and Development Expense of Revenue |
15.30% | 16.96% | 18.20% | 17.81% | |
Selling, General and Administrative Expense of Revenue |
49.97% | 56.35% | 51.71% | 55.00% | |
Intangible Assets out of Total Assets |
0.41 | 0.10 | 0.18 | 0.18 | |
Share Based Compensation of Revenue |
6.93% | 8.07% | 8.33% | 7.46% | |
Graham Net Nets |
0.04 | 0.22 | 0.19 | 0.15 | |
Graham Number |
22.42 | 20.00 | 0.00 | 0.00 | |
Earnings Yield |
3.83% | 7.54% | (0.92%) | (2.12%) | |
Free Cash Flow Yield |
1.72% | 5.67% | 7.13% | 3.44% | |
Revenue per Share |
2.67 | 2.56 | 2.30 | 2.03 | |
Operating CF per Share |
0.24 | 0.59 | 0.08 | 0.40 | |
Capex per Share |
(0.03) | (0.04) | (0.07) | (0.04) | |
Free Cash Flow per Share |
0.21 | 0.56 | 0.01 | 0.36 | |
Cash per Share |
4.81 | 7.26 | 3.66 | 3.33 | |
Shareholders Equity per Share |
8.97 | 8.27 | 6.13 | 5.69 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.97 | 8.27 | 6.13 | 5.69 | |
Free Cash Flow |
11.10 | 28.75 | 0.51 | 19.39 | |
Working Capital |
182.32 | 335.53 | 190.24 | 167.28 | |
Capital Expenditures |
(1.61) | (1.86) | (3.82) | (1.97) | |
Net Current Asset Value |
147.30 | 321.83 | 171.87 | 147.01 | |
EV/EBIT |
26.95 | 10.13 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.03 | 0.02 | |
Price to Operating Income |
29.08 | 13.57 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
47.79 | 50.87 | 58.04 | 53.62 | |
Average Payables |
11.20 | 9.68 | 8.57 | 8.84 | |
Average Inventory |
18.74 | 17.45 | 24.67 | 23.10 | |
Average Assets |
536.88 | 488.62 | 450.35 | 452.14 | |
Average Common Equity |
389.30 | 376.48 | 346.44 | 340.77 |
Columns are period end dates · fundamentals updated 5 Nov 2026